Sanara MedTech Reports FY25 Revenue Up 19% to $103.1M, Reiterates 2026 Guidance
SMTI is trading near its 52-week low of $17.99 (2.3% above the low) on elevated volume (1.9× avg).
Summary
Sanara MedTech Inc. announced its full-year 2025 financial results, reporting net revenue of $103.1 million, a 19% increase year-over-year, and Q4 revenue of $27.5 million. The company also reported full-year Adjusted EBITDA of $17.0 million but a net loss from continuing operations of $0.4 million. Sanara MedTech reiterated its 2026 revenue guidance of $116 million to $121 million, representing approximately 13%-17% growth. This earnings report provides a critical update on the company's financial performance and future outlook. While the strong revenue growth is positive, the continued net loss will be a key focus for investors. Traders will be closely watching market reaction to these mixed results, particularly as the stock trades near its 52-week low, and assessing the path to sustained profitability.
At the time of this announcement, SMTI was trading at $18.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.9M. The 52-week trading range was $17.99 to $35.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.